Cargando…

The efficacy and safety of ginger supplementation in patients with multiple sclerosis: A rationale and study protocol for a double‐blind randomized controlled trial

BACKGROUND AND AIMS: Multiple sclerosis (MS) is a chronic disease characterized by axonal damage, demyelination, inflammation, oxidative stress, and immune cell infiltration. This disease is the first cause of nontraumatic disability in young adults leading to a decline in patients' quality of...

Descripción completa

Detalles Bibliográficos
Autores principales: Foshati, Sahar, Poursadeghfard, Maryam, Heidari, Zahra, Amani, Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771858/
https://www.ncbi.nlm.nih.gov/pubmed/36570345
http://dx.doi.org/10.1002/hsr2.1004
_version_ 1784854907432468480
author Foshati, Sahar
Poursadeghfard, Maryam
Heidari, Zahra
Amani, Reza
author_facet Foshati, Sahar
Poursadeghfard, Maryam
Heidari, Zahra
Amani, Reza
author_sort Foshati, Sahar
collection PubMed
description BACKGROUND AND AIMS: Multiple sclerosis (MS) is a chronic disease characterized by axonal damage, demyelination, inflammation, oxidative stress, and immune cell infiltration. This disease is the first cause of nontraumatic disability in young adults leading to a decline in patients' quality of life. Patients with MS may also suffer from gastrointestinal symptoms due to the disease or prescription drugs. Unfortunately, no treatment for MS has been discovered yet, and prescribed drugs can only help control its clinical course. Interestingly, recent animal studies have shown positive effects of ginger administration in the MS model. Therefore, we aim to determine the effect of ginger supplementation on neurofilament light chain, matrix metalloproteinase‐9, interleukin‐17, nitric oxide, complete and differential blood counts, disability status, quality of life, gastrointestinal symptoms, and body mass index (BMI) in MS patients. METHODS: This study is a double‐blind randomized controlled trial. Fifty‐two patients with relapsing‐remitting MS will be assigned to intervention and control groups using stratified permuted block randomization. The intervention and control groups will take 1500 mg/day ginger and placebo (as corn) supplements for 12 weeks, respectively. All outcomes will be assessed before and after the trial. Serum concentrations of neurofilament light chain, matrix metalloproteinase‐9, and interleukin‐17 will be measured by enzyme‐linked immunosorbent assay. Nitric oxide serum levels will be detected using colorimetry. Complete and differential blood counts will be assessed by an automated hematology analyzer. Disability status, quality of life, and gastrointestinal symptoms will be evaluated by the Expanded Disability Status Scale, MS Impact Scale, and Visual Analog Scale, respectively. BMI will be calculated by dividing weight in kilograms by height in meters squared. Potential side effects of ginger supplementation will also be closely monitored during the study. TRIAL REGISTRATION: This protocol was registered at the Iranian Registry of Clinical Trials (www.irct.ir) under the registration number IRCT20180818040827N3.
format Online
Article
Text
id pubmed-9771858
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-97718582022-12-23 The efficacy and safety of ginger supplementation in patients with multiple sclerosis: A rationale and study protocol for a double‐blind randomized controlled trial Foshati, Sahar Poursadeghfard, Maryam Heidari, Zahra Amani, Reza Health Sci Rep Study Protocols BACKGROUND AND AIMS: Multiple sclerosis (MS) is a chronic disease characterized by axonal damage, demyelination, inflammation, oxidative stress, and immune cell infiltration. This disease is the first cause of nontraumatic disability in young adults leading to a decline in patients' quality of life. Patients with MS may also suffer from gastrointestinal symptoms due to the disease or prescription drugs. Unfortunately, no treatment for MS has been discovered yet, and prescribed drugs can only help control its clinical course. Interestingly, recent animal studies have shown positive effects of ginger administration in the MS model. Therefore, we aim to determine the effect of ginger supplementation on neurofilament light chain, matrix metalloproteinase‐9, interleukin‐17, nitric oxide, complete and differential blood counts, disability status, quality of life, gastrointestinal symptoms, and body mass index (BMI) in MS patients. METHODS: This study is a double‐blind randomized controlled trial. Fifty‐two patients with relapsing‐remitting MS will be assigned to intervention and control groups using stratified permuted block randomization. The intervention and control groups will take 1500 mg/day ginger and placebo (as corn) supplements for 12 weeks, respectively. All outcomes will be assessed before and after the trial. Serum concentrations of neurofilament light chain, matrix metalloproteinase‐9, and interleukin‐17 will be measured by enzyme‐linked immunosorbent assay. Nitric oxide serum levels will be detected using colorimetry. Complete and differential blood counts will be assessed by an automated hematology analyzer. Disability status, quality of life, and gastrointestinal symptoms will be evaluated by the Expanded Disability Status Scale, MS Impact Scale, and Visual Analog Scale, respectively. BMI will be calculated by dividing weight in kilograms by height in meters squared. Potential side effects of ginger supplementation will also be closely monitored during the study. TRIAL REGISTRATION: This protocol was registered at the Iranian Registry of Clinical Trials (www.irct.ir) under the registration number IRCT20180818040827N3. John Wiley and Sons Inc. 2022-12-21 /pmc/articles/PMC9771858/ /pubmed/36570345 http://dx.doi.org/10.1002/hsr2.1004 Text en © 2022 The Authors. Health Science Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Study Protocols
Foshati, Sahar
Poursadeghfard, Maryam
Heidari, Zahra
Amani, Reza
The efficacy and safety of ginger supplementation in patients with multiple sclerosis: A rationale and study protocol for a double‐blind randomized controlled trial
title The efficacy and safety of ginger supplementation in patients with multiple sclerosis: A rationale and study protocol for a double‐blind randomized controlled trial
title_full The efficacy and safety of ginger supplementation in patients with multiple sclerosis: A rationale and study protocol for a double‐blind randomized controlled trial
title_fullStr The efficacy and safety of ginger supplementation in patients with multiple sclerosis: A rationale and study protocol for a double‐blind randomized controlled trial
title_full_unstemmed The efficacy and safety of ginger supplementation in patients with multiple sclerosis: A rationale and study protocol for a double‐blind randomized controlled trial
title_short The efficacy and safety of ginger supplementation in patients with multiple sclerosis: A rationale and study protocol for a double‐blind randomized controlled trial
title_sort efficacy and safety of ginger supplementation in patients with multiple sclerosis: a rationale and study protocol for a double‐blind randomized controlled trial
topic Study Protocols
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771858/
https://www.ncbi.nlm.nih.gov/pubmed/36570345
http://dx.doi.org/10.1002/hsr2.1004
work_keys_str_mv AT foshatisahar theefficacyandsafetyofgingersupplementationinpatientswithmultiplesclerosisarationaleandstudyprotocolforadoubleblindrandomizedcontrolledtrial
AT poursadeghfardmaryam theefficacyandsafetyofgingersupplementationinpatientswithmultiplesclerosisarationaleandstudyprotocolforadoubleblindrandomizedcontrolledtrial
AT heidarizahra theefficacyandsafetyofgingersupplementationinpatientswithmultiplesclerosisarationaleandstudyprotocolforadoubleblindrandomizedcontrolledtrial
AT amanireza theefficacyandsafetyofgingersupplementationinpatientswithmultiplesclerosisarationaleandstudyprotocolforadoubleblindrandomizedcontrolledtrial
AT foshatisahar efficacyandsafetyofgingersupplementationinpatientswithmultiplesclerosisarationaleandstudyprotocolforadoubleblindrandomizedcontrolledtrial
AT poursadeghfardmaryam efficacyandsafetyofgingersupplementationinpatientswithmultiplesclerosisarationaleandstudyprotocolforadoubleblindrandomizedcontrolledtrial
AT heidarizahra efficacyandsafetyofgingersupplementationinpatientswithmultiplesclerosisarationaleandstudyprotocolforadoubleblindrandomizedcontrolledtrial
AT amanireza efficacyandsafetyofgingersupplementationinpatientswithmultiplesclerosisarationaleandstudyprotocolforadoubleblindrandomizedcontrolledtrial